U.S. Administrative Headquarters
Morris Corporate Center III, 400 Interpace Parkway
Tel: 1 (862) 261-7000
About Allergan, Inc.
Allergan plc (AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry.
We’re Looking for the World’s Best
At Allergan, we are committed to recruiting and retaining the industry’s best and brightest employees and are proud to offer opportunities for military veterans at all levels across our company. We offer business, scientific, technical, engineering, sales & marketing and a variety of other positions here in the U.S. and around the world.
At Allergan, you will find an entrepreneurial style work environment where employees and employee teams are encouraged to apply their unique talents to grow, contribute, innovate and excel. We welcome your ideas. We provide the support, resources and encouragement that enable you to take your career to new heights. We focus on challenging you, challenging ourselves and driving success.
Commit to your future and join us. Learn more about our exciting career opportunities at www.allergan.com/careers.
Founder: Gavin S. Herbert
CEO: Brenton L. Saunders
CFO: Maria Teresa Hilado
Please click here for clinical trial information.
912 articles with Allergan, Inc.
The U.S. Supreme Court delivered a blow to the nation’s pharmaceutical industry when it upheld the constitutionality of Inter Partes Review (IPR).
Urovant Sciences has been busy the past few weeks. In March the company initiated a Phase III trial for an overactive bladder treatment, strengthened its management team and established a U.S. headquarters in Irvine, California.
4/24/2018Takeda Pharmaceutical has come back with an improved bid for Shire, making it the fifth round of talks.
Takeda Pharmaceutical has come back to the bargaining table with a juicier bid for Shire. Yesterday, Takeda’s $60 billion-plus bid for Shire took an odd turn late yesterday when Dublin, Ireland-based Allergan was reported to be in talks with Shire as well. However, by the end of the day, Allergan...
UPDATED: Shire Rejects Takeda’s $60 Billion Acquisition Bid and Allergan Reportedly In Talks with...
4/19/2018Takeda Pharmaceutical has made an official bid to acquire London’s Shire for about $60 billion. And in breaking news, Shire rejected the bid, saying it undervalued the company.
As previously reported, Allergan plc ("Allergan") is in the process of evaluating a full range of potential strategic actions that will create value for shareholders, such as divestitures, combinations and acquisitions. The company has hired multiple financial advisors to assist in the review of these options.
Utah’s Salt Lake County is the latest governing body to enter the legal battle against opioid manufacturers, distributors and prescribers. Governments are seeking financial restitution for the funds they have spent on battling addiction to prescription opioid medications.
Allergan Announces Launch of the TrueTear® Intranasal Neurostimulation Device During 2018 ASCRS-ASOA Annual Meeting
Allergan plc announced the official launch of TrueTear®, the first and only FDA-cleared device developed to temporarily increase tear production during neurostimulation in adult patients.
4/13/2018There has been speculation for several years whether Pfizer Inc. would consider buying Bristol-Myers Squibb. That appears to have been laid to rest by comments made by Pfizer’s chief executive officer, Ian Read.
Investors in Ionis Pharmaceuticals are happy this morning after the company announced it struck another licensing deal with AstraZeneca that has the potential to yield up to $330 million.
If a brand name drug loses patent protection, that often marks the date when companies can begin marketing generic versions of the drug. However, this has grown more complicated with the approvals of biosimilars.
As legal battles over opioid drugs slowly move through the courts the U.S. Department of Justice is adding its weight to the matter. This week the DOJ asked the courts for permission to help settle disputes brought by state and local governments against opioid manufacturers and distributors.
Allergan and its developmental partner Gedeon Richter Ltd. are eying an add-on approval from the U.S. Food and Drug Administration for a depression treatment based on new Phase III data released Tuesday.
The $40 billion market for nonalcoholic steatohepatitis (NASH) is becoming a little more crowded. Less than one year after launching Terns Pharmaceuticals acquired exclusive licensing rights to three small molecule therapeutic NASH candidates from Eli Lilly.
Allergan and Richter Announce Positive Topline Results from Third of Three Pivotal Trials of Cariprazine in Bipolar I Depression
Primary endpoint was met in the study evaluating patients with acute bipolar I depression treated with cariprazine 1.5 mg versus placebo.
Allergan plc announced it has received the 2018 ENERGY STAR® Partner of the Year Sustained Excellence Award.
Biohaven Pharmaceutical released positive top-line results from two Phase III clinical trials of rimegepant for migraine. Despite the positive data, shares were down more than 30 percent in early trading this morning.
Here’s a look at eight biopharma companies with upcoming catalysts.
Seven months after Prevail Therapeutics launched, the company has secured $75 million in Series A financing to support the development of gene therapies for Parkinson’s disease.
Mylan N.V. signed a global collaboration and license deal with Revance Therapeutics to develop and market a biosimilar to Botox.